Global Information
회사소개 | 문의 | 비교리스트

세계의 웨어러블 인젝터 시장 성장 기회와 산업 예측(2021-2030년) : 종류별, 사용법별, 기술별, 주사 메커니즘별, 치료 분야별, 최종사용자별

Wearable Injectors Market By Type, Usage, Technology, Mechanism Of Injection, Therapeutic Area, and End User : Global Opportunity Analysis And Industry Forecast, 2021--2030

리서치사 Allied Market Research
발행일 2021년 12월 상품코드 1059574
페이지 정보 영문 344 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 4,125 ₩ 5,256,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 6,168 ₩ 7,859,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,929 ₩ 8,828,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,663 ₩ 13,586,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 웨어러블 인젝터 시장 성장 기회와 산업 예측(2021-2030년) : 종류별, 사용법별, 기술별, 주사 메커니즘별, 치료 분야별, 최종사용자별 Wearable Injectors Market By Type, Usage, Technology, Mechanism Of Injection, Therapeutic Area, and End User : Global Opportunity Analysis And Industry Forecast, 2021--2030
발행일 : 2021년 12월 페이지 정보 : 영문 344 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 웨어러블 인젝터 시장 규모는 2020년 50억 2,220만 달러에서 예측기간 중 15.3%의 CAGR로 확대되고, 2030년에는 195억 1,890만 달러 규모로 성장할 것으로 예측됩니다.

첨단 웨어러블 인젝터 개발과 기존 정맥주사에 대한 우위성이 시장 성장을 지지하고 있습니다. 또한 신종 코로나바이러스 감염증(COVID-19)의 영향으로 재택 치료 채용이 증가한 점도 시장 성장을 추진하고 있습니다. 또한 암, 당뇨병, 신장병, 호흡기질환, 관절염 등의 만성질환 유병률 상승, 노년 인구 증가 등의 요인도 시장 성장에 기여하고 있습니다.

세계의 웨어러블 인젝터(Wearable Injectors) 시장을 조사했으며, 시장 정의와 개요, 시장 영향요인 분석, 특허 동향, 임상시험 분석, 시장 규모 추정과 예측, 종류·사용법·기술·주사 메커니즘·치료 분야·최종사용자·지역/주요 국가 등 각종 세분화별 내역, 경쟁 상황, 주요 기업 개요 등을 정리했습니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

  • 시장 정의와 범위
  • 주요 조사 결과
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석
  • COVID-19 : 영향 분석
  • 특허 분석
  • 임상시험 분석

제4장 웨어러블 인젝터 시장 : 종류별

  • 개요
  • 온 바디
  • 오프 바디
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제5장 웨어러블 인젝터 시장 : 사용법별

  • 개요
  • 일회용
  • 반 재사용 가능
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제6장 웨어러블 인젝터 시장 : 기술별

  • 개요
  • 전자식 인젝터
  • 기계식 인젝터
  • 기타
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제7장 웨어러블 인젝터 시장 : 주사 메커니즘별

  • 개요
  • 모터
  • 스프링
  • 확장 배터리
  • 로터리 펌프
  • 접이식 레저부아
  • 가압 가스
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제8장 웨어러블 인젝터 시장 : 치료 분야별

  • 개요
  • 당뇨병
  • 종양
  • 심혈관질환
  • 기타
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제9장 웨어러블 인젝터 시장 : 최종사용자별

  • 개요
  • 클리닉
  • 병원
  • 외래 수술 센터
  • 재택 케어
  • 기타
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제10장 웨어러블 인젝터 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카, 중동 및 아프리카
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 웨어러블 인젝터 시장 : 종류별
    • 웨어러블 인젝터 시장 : 사용법별
    • 웨어러블 인젝터 시장 : 기술별
    • 웨어러블 인젝터 시장 : 주사 메커니즘별
    • 웨어러블 인젝터 시장 : 치료 분야별
    • 웨어러블 인젝터 시장 : 최종사용자별
    • 시장 규모와 예측 : 국가별

제11장 기업 개요

  • BECTON DICKINSON AND COMPANY
  • BUHLER MOTOR GmbH
  • ENABLE INJECTION
  • EOFLOW CO. LTD.
  • GERRESHEIMER ADVANCED TECHNOLOGIES
  • INSULET CORPORATION
  • MEDTRONIC PLC.
  • UNITED THERAPEUTICS CORPORATION.
  • WEST PHARMACEUTICAL SERVICES, INC
  • YPSOMED AG
KSM 22.03.07

LIST OF TABLES

  • TABLE 01.WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 02.WEARABLE INJECTOR MARKET FOR ON-BODY INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.WEARABLE INJECTOR MARKET FOR OFF-BODY , BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 05.WEARABLE INJECTOR MARKET FOR DISPOSABLE INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.WEARABLE INJECTOR MARKET FOR SEMI-REUSABLE INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 07.WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 08.WEARABLE INJECTOR MARKET FOR ELECTRONIC INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.WEARABLE INJECTOR MARKET FOR MECHANICAL INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.WEARABLE INJECTOR MARKET FOR OTHER INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 12.WEARABLE INJECTOR MARKET FOR MOTOR DRIVEN INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.WEARABLE INJECTOR MARKET FOR SPRING-BASED INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.WEARABLE INJECTOR MARKET FOR MOTOR DRIVEN INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.WEARABLE INJECTOR MARKET FOR MOTOR DRIVEN INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.WEARABLE INJECTOR MARKET FOR COLLAPSIBLE RESERVOIR, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.WEARABLE INJECTOR MARKET FOR PRESSURIZED GAS INJECTORS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 18.WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 19.WEARABLE INJECTOR MARKET FOR DIABETES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 20.WEARABLE INJECTOR MARKET FOR ONCOLOGY, BY REGION, 2020-2030 ($MILLION)
  • TABLE 21.WEARABLE INJECTOR MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2020-2030 ($MILLION)
  • TABLE 22.WEARABLE INJECTOR MARKET FOR OTHER, BY REGION, 2020-2030 ($MILLION)
  • TABLE 23.WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 24.WEARABLE INJECTOR MARKET FOR CLINICS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 25.WEARABLE INJECTOR MARKET FOR HOSPITALS, 2020-2030 ($MILLION)
  • TABLE 26.WEARABLE INJECTOR MARKET FOR AMBULATORY SURGERY CENTERS 2020-2030 ($MILLION)
  • TABLE 27.WEARABLE INJECTOR MARKET FOR HOME CARE SETTINGS 2020-2030 ($MILLION)
  • TABLE 28.WEARABLE INJECTOR MARKET FOR OTHER, 2020-2030 ($MILLION)
  • TABLE 29.WEARABLE INJECTOR MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 30.NORTH AMERICA WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 31.NORTH AMERICA WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 32.NORTH AMERICA WEARABLE INJECTOR, BY TEHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 33.NORTH AMERICA WEARABLE INJECTOR, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 34.NORTH AMERICA WEARABLE INJECTOR, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 35.NORTH AMERICA WEARABLE INJECTOR, BY END USER, 2020-2030 ($MILLION)
  • TABLE 36.NORTH AMERICA WEARABLE INJECTOR MARKET WAS VALUED, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 37.U.S. WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 38.U.S. WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 39.U.S. WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 40.U.S. WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 41.U.S. WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 42.U.S. WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 43.CANADA WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 44.CANADA WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 45.CANADA WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 46.CANADA WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 47.CANADA WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 48.CANADA WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 49.MEXICO WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 50.MEXICO WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 51.MEXICO WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 52.MEXICO WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 53.MEXICO WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 54.MEXICO WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 55.EUROPE WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 56.EUROPE WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 57.EUROPE WEARABLE INJECTOR, BY TEHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 58.EUROPE WEARABLE INJECTOR, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 59.EUROPE WEARABLE INJECTOR, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 60.EUROPE WEARABLE INJECTOR, BY END USER, 2020-2030 ($MILLION)
  • TABLE 61.EUROPE WEARABLE INJECTOR MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 62.GERMANY WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 63.GERMANY WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 64.GERMANY WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 65.GERMANY WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 66.GERMANY WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 67.GERMANY WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 68.FRANCE WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 69.FRANCE WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 70.FRANCE WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 71.FRANCE WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 72.FRANCE WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 73.FRANCE WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 74.UK WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 75.UK WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 76.UK WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 77.UK WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 78.UK WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 79.UK WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 80.ITALY WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 81.ITALY WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 82.ITALYWEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 83.ITALY WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 84.ITALYWEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 85.ITALY WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 86.SPAIN WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 87.SPAIN WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 88.SPAIN WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 89.SPAIN WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 90.SPAIN WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 91.SPAIN WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 92.REST OF EUROPE WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 93.REST OF EUROPE WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 94.REST OF EUROPE WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 95.REST OF EUROPE WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 96.REST OF EUROPE WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 97.REST OF EUROPE WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 98.ASIA-PACIFIC WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 99.ASIA-PACIFIC WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 100.ASIA-PACIFIC WEARABLE INJECTOR, BY TEHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 101.ASIA-PACIFIC WEARABLE INJECTOR, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 102.ASIA-PACIFIC WEARABLE INJECTOR, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 103.ASIA-PACIFIC WEARABLE INJECTOR, BY END USER, 2020-2030 ($MILLION)
  • TABLE 104.ASIA-PACIFIC WEARABLE INJECTOR MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 105.JAPAN WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 106.JAPAN WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 107.JAPAN WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 108.JAPAN WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 109.JAPAN WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 110.JAPAN WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 111.CHINA WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 112.CHINA WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 113.CHINA WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 114.CHINA WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 115.CHINA WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 116.CHINA WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 117.AUSTRALIA WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 118.AUSTRALIA WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 119.AUSTRALIA WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 120.AUSTRALIA WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 121.AUSTRALIA WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 122.AUSTRALIA WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 123.INDIA WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 124.INDIA WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 125.INDIA WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 126.INDIA WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 127.INDIA WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 128.INDIA WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 129.SOUTH KOREA WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 130.SOUTH KOREA WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 131.SOUTH KOREA WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 132.SOUTH KOREA WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 133.SOUTH KOREA WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 134.SOUTH KOREA WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 135.REST OF ASIA-PACIFIC REST OF ASIA-PACIFIC WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 136.REST OF ASIA-PACIFIC REST OF ASIA-PACIFIC WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 137.REST OF ASIA-PACIFIC REST OF ASIA-PACIFIC WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 138.REST OF ASIA-PACIFIC WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 139.REST OF ASIA-PACIFIC WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 140.REST OF ASIA-PACIFIC WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 141.LAMEA WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 142.LAMEA WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 143.LAMEA WEARABLE INJECTOR, BY TEHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 144.LAMEA WEARABLE INJECTOR, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 145.LAMEA WEARABLE INJECTOR, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 146.LAMEA WEARABLE INJECTOR, BY END USER, 2020-2030 ($MILLION)
  • TABLE 147.LAMEA WEARABLE INJECTOR MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 148.BRAZIL WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 149.BRAZIL WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 150.BRAZIL WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 151.BRAZIL WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 152.BRAZIL WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 153.BRAZIL WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 154.SAUDI ARABIA WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 155.SAUDI ARABIA WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 156.SAUDI ARABIA WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 157.SAUDI ARABIA WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 158.SAUDI ARABIA WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 159.SAUDI ARABIA WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 160.SOUTH AFRICA WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 161.SOUTH AFRICA WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 162.SOUTH AFRICA WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 163.SOUTH AFRICA WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 164.SOUTH AFRICA WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 165.SOUTH AFRICA WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 166.REST OF LAMEA WEARABLE INJECTOR MARKET, BY TYPE, 2020-2030 ($MILLION)
  • TABLE 167.REST OF LAMEA WEARABLE INJECTOR MARKET, BY USAGE, 2020-2030 ($MILLION)
  • TABLE 168.REST OF LAMEA WEARABLE INJECTOR MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 169.REST OF LAMEA WEARABLE INJECTOR MARKET, BY MECHANISM OF ACTION, 2020-2030 ($MILLION)
  • TABLE 170.REST OF LAMEA WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA, 2020-2030 ($MILLION)
  • TABLE 171.REST OF LAMEA WEARABLE INJECTOR MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 172.BD: COMPANY SNAPSHOT
  • TABLE 173.BD: OPERATING SEGMENTS
  • TABLE 174.BD: PRODUCT PORTFOLIO
  • TABLE 175.BUHLER: COMPANY SNAPSHOT
  • TABLE 176.BUHLER OPERATING SEGMENTS
  • TABLE 177.BUHLER: PRODUCT PORTFOLIO
  • TABLE 178.ENABLE: COMPANY SNAPSHOT
  • TABLE 179.ENABLE: OPERATING SEGMENTS
  • TABLE 180.ENABLE: PRODUCT PORTFOLIO
  • TABLE 181.ENABLE.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182.EOFLOW: COMPANY SNAPSHOT
  • TABLE 183.EOFLOW: OPERATING SEGMENTS
  • TABLE 184.EOFLOW: PRODUCT PORTFOLIO
  • TABLE 185.GERRESHEIMER: COMPANY SNAPSHOT
  • TABLE 186.GERRESHEIMER: OPERATING SEGMENTS
  • TABLE 187.GERRESHEIMER: PRODUCT PORTFOLIO
  • TABLE 188.GERRESHEIMER.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 189.INSULET: COMPANY SNAPSHOT
  • TABLE 190.INSULET SEGMENTS
  • TABLE 191.INSULET: PRODUCT PORTFOLIO
  • TABLE 192.INSULET.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 193.MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 194.MEDTRONIC: OPERATING SEGMENT
  • TABLE 195.MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 196.UNITED THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 197.UNITED THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 198.UNITED THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 199.XX.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 200.WEST: COMPANY SNAPSHOT
  • TABLE 201.WEST: OPERATING SEGMENTS
  • TABLE 202.WEST: PRODUCT PORTFOLIO
  • TABLE 203.YPSOMED: COMPANY SNAPSHOT
  • TABLE 204.YPSOMED: OPERATING SEGMENTS
  • TABLE 205.YPSOMED: PRODUCT PORTFOLIO
  • TABLE 206.YPSOMED.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01.WEARABLE INJECTOR MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.PATENTS ANALYSIS BY YEAR, 2018 THROUGH 2021
  • FIGURE 14.YEAR 2020 PATENT ANALYSIS, BY COUNTRY
  • FIGURE 15.WEARABLE INJECTORS CLINICAL TRIALS, BY REGION, 2018-2021
  • FIGURE 16.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR ON BODY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR OFF-BODY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR DISPOSABLE INJECTORS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 19.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR SEMI-REUSABLE INJECTORS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR ELECTRONIC INJECTORS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR MECHANICAL INJECTORS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR OTHER INJECTORS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR MOTOR DRIVEN INJECTORS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR SPRING-BASED INJECTORS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 25.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR MOTOR DRIVEN INJECTORS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 26.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR MOTOR DRIVEN INJECTORS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 27.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR COLLAPSIBLE RESERVOIR, BY COUNTRY, 2020-2030 (%)
  • FIGURE 28.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR PRESSURIZED GAS INJECTORS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 29.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR DIABETES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 30.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2030 (%)
  • FIGURE 31.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2020-2030 (%)
  • FIGURE 32.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR OTHER, BY COUNTRY, 2020-2030 (%)
  • FIGURE 33.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR CLINICS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 34.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR HOSPITALS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 35.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 36.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 37.COMPARATIVE ANALYSIS OF WEARABLE INJECTOR MARKET FOR OTHER, BY COUNTRY, 2020-2030 (%)
  • FIGURE 38.BD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 39.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 40.BD: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 41.BUHLER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 42.BUHLER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 43.BUHLER: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 44.GERRESHEIMER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 45.GERRESHEIMER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 46.GERRESHEIMER: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 47.INSULET: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 48.INSULET: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 49.INSULET: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 50.MEDTRONIC: NET SALES, 2020 ($MILLION)
  • FIGURE 51.MEDTRONIC: REVENUE SHARE PER SEGMENT 2020(%)
  • FIGURE 52.MEDTRONIC: REVENUE SHARE BY REGION 2020(%)
  • FIGURE 53.UNITED THERAPEUTICS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 54.UNITED THERAPEUTICS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 55.UNITED THERAPEUTICS: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 56.WEST: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 57.WEST: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 58.WEST: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 59.YPSOMED: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 60.YPSOMED: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 61.YPSOMED: REVENUE SHARE BY REGION, 2020(%)

The global wearable injectors market was valued at $5,022.2 million in 2020, and is projected to reach $19,518.9 million by 2030, registering a CAGR of 15.3% from 2021 to 2030.

Wearable injectors are devices that are comfortably worn on the body and the drug such as insulin is subcutaneously administered over a pre-programmed period spanning seconds or hours. Upon full injection of the dose, they are removed from the body and conveniently disposed. Wearable injectors are economical, when compared to intravenous (IV) infusion drug administration at home, therefore, they have the potential to save a substantial amount of money in total healthcare expenditures. Wearable injectors allow self-administration of a therapy without medical supervision and reduce burden on healthcare practitioners. In addition, they are suitable for highly viscous fluids such as therapeutic proteins like monoclonal antibodies, cytokinin, insulin, and antigens. The biologic drugs are highly viscous in nature which poses substantial challenges in drug delivery owing to their large size and susceptibility to degradation, hence large volume wearable injectors used to deliver such biologic drugs to the patients. For instance, Eitan Medical, a leading manufacturer of wearable injectors, offers Sorrel, a wearable injector platform with different capacities of drug delivery ranging up to 25 ml.

Development of advanced wearable injectors and advantages over traditional IV infusion drives growth of the wearable injector market. In addition, increase in adoption of home-based treatments, owing to the impact of COVID-19 propel growth of the wearable injector market. Wearable injectors can release drug throughout the set period with specific time intervals, thus it can be used for long term therapy.

Rise in prevalence of chronic diseases such as cancer, diabetes, kidney diseases, respiratory diseases, and arthritis contributes toward growth of the market. For instance, according to the World Health Organization (WHO) in 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes in the world. Cancer has become one of the leading cause of death worldwide. As per the American Cancer Society Journal, an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020, globally. Rise in geriatric population also contributes toward growth of the market. Wearable injectors are useful for geriatric patients receiving daily medication, giving them convenient experience. For instance, as per data by the Population Reference Bureau (PRB), in 2019, about 52.76 million people were over the age of 65 in the U.S.

However, some drugs are highly potent and may produce toxic effects such as anti-cancer requires physician monitoring, which limits usability of wearable injectors. In addition, high cost associated with manufacturing of devices in developing and underdeveloped countries also limit growth of the market. Moreover, a single type of wearable injector is not suitable for all drugs, hence manufacturers, while designing a device, focus on specific category of medication, which limits its usage.

The wearable injector market is segmented on the basis of type, usage, technology, mechanism of injection, therapeutic area, end user, and region. By type, the market is divided into on body (adhesive patch), off body (belt held), and hand held. By usage, it is classified into disposable and semi-reusable. By technology, it is classified into electronic injectors, mechanical injectors, and others. By mechanism of injection, it is categorized as motor driven, spring driven, expanding battery, rotary pump, collapsible reservoir, and pressurized gas. By therapeutic area, it is divided into diabetes, oncology, cardiovascular disease, infectious disease, and auto immune disorder. By end user, it is divided into clinics, hospitals, ambulatory surgery centers, home care settings, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global wearable injector market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global wearable injector market growth

KEY MARKET SEGMENTS

By Type

  • On body
  • Off body

By Usage

  • Disposable
  • Semi-reusable

By Technology

  • Electronic injectors
  • Mechanical injectors
  • Others

By Mechanism of Injection

  • Motor driven
  • Spring driven
  • Expanding battery
  • Rotary pump
  • Collapsible reservoir
  • Pressurized gas

By Therapeutic Area

  • Diabetes
  • Oncology
  • Cardiovascular disease
  • Other

By End User

  • Clinics
  • Hospital
  • Ambulatory surgery centers
  • Home care setting
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Enable injections
  • United therapeutics (Steadymed therapeutics, inc.)
  • Insulet corporation
  • Medtronic plc
  • Sensile medical ag
  • West pharmaceutical services, inc.
  • Becton, dickinson and company
  • Buhler motor gmbh
  • Ypsomed
  • Eoflow

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

  • Amgen
  • Sorrel medical
  • Philips

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Shift of healthcare system toward home-based treatment due to COVID-19
      • 3.5.1.2.Rise in demand for quality and affordable patient care
      • 3.5.1.3.Advancements in wearable injectors
    • 3.5.2.Restraint
      • 3.5.2.1.Low volume of administration and nature of drugs
    • 3.5.3.Opportunity
      • 3.5.3.1.Increase in prevalence of chronic disorders.
    • 3.5.4.Impact analysis
  • 3.6.Impact analysis of COVID-19 on the wearable injector market
  • 3.7.Patent Analysis (2018-2021)
    • 3.7.1.Patent analysis, by year
    • 3.7.2.Patent analysis for year 2020, by country
  • 3.8.Clinical Trial Analysis (2018-2021)

CHAPTER 4:WEARABLE INJECTOR MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.On body
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast
    • 4.2.3.Market analysis, by country
  • 4.3.Off-body
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country

CHAPTER 5:WEARABLE INJECTOR MARKET, BY USAGE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Disposable
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Semi-reusable
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.Market size and forecast, by region
    • 5.3.3.Market analysis, by country

CHAPTER 6:WEARABLE INJECTOR MARKET, BY TECHNOLOGY

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Electronic injector
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.Market size and forecast, by region
    • 6.2.3.Market analysis, by country
  • 6.3.Mechanical injectors
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by region
    • 6.3.3.Market analysis, by country
  • 6.4.Other
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by region
    • 6.4.3.Market analysis, by country

CHAPTER 7:WEARABLE INJECTOR MARKET, BY MECHANISM OF INJECTION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.Motor driven
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by region
    • 7.2.3.Market analysis, by country
  • 7.3.Spring-based
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by region
    • 7.3.3.Market analysis, by country
  • 7.4.Expanding battery
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by region
    • 7.4.3.Market analysis, by country
  • 7.5.Rotary pump
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by region
    • 7.5.3.Market analysis, by country
  • 7.6.Collapsible reservoir
    • 7.6.1.Key market trends, growth factors, and opportunities
    • 7.6.2.Market size and forecast, by region
    • 7.6.3.Market analysis, by country
  • 7.7.Pressurized gas
    • 7.7.1.Key market trends, growth factors, and opportunities
    • 7.7.2.Market size and forecast, by region
    • 7.7.3.Market analysis, by country

CHAPTER 8:WEARABLE INJECTOR MARKET, BY THERAPEUTIC AREA

  • 8.1.Overview
    • 8.1.1.Market size and forecast
  • 8.2.Diabetes
    • 8.2.1.Key market trends, growth factors, and opportunities
    • 8.2.2.Market size and forecast, by region
    • 8.2.3.Market analysis, by country
  • 8.3.Oncology
    • 8.3.1.Key market trends, growth factors, and opportunities
    • 8.3.2.Market size and forecast, by region
    • 8.3.3.Market analysis, by country
  • 8.4.Cardiovascular diseases
    • 8.4.1.Key market trends, growth factors, and opportunities
    • 8.4.2.Market size and forecast, by region
    • 8.4.3.Market analysis, by country
  • 8.5.Others
    • 8.5.1.Key market trends, growth factors, and opportunities
    • 8.5.2.Market size and forecast, by region
    • 8.5.3.Market analysis, by country

CHAPTER 9:WEARABLE INJECTOR MARKET, BY END USER

  • 9.1.Overview
    • 9.1.1.Market size and forecast
  • 9.2.Clinics
    • 9.2.1.Key market trends, growth factors, and opportunities
    • 9.2.2.Market size and forecast, by region
    • 9.2.3.Market analysis, by country
  • 9.3.Hospitals
    • 9.3.1.Key market trends, growth factors, and opportunities
    • 9.3.2.Market size and forecast, by region
    • 9.3.3.Market analysis, by country
  • 9.4.Ambulatory surgery centers
    • 9.4.1.Key market trends, growth factors, and opportunities
    • 9.4.2.Market size and forecast, by region
    • 9.4.3.Market analysis, by country
  • 9.5.Home care settings
    • 9.5.1.Key market trends, growth factors, and opportunities
    • 9.5.2.Market size and forecast, by region
    • 9.5.3.Market analysis, by country
  • 9.6.Others
    • 9.6.1.Key market trends, growth factors, and opportunities
    • 9.6.2.Market size and forecast, by region
    • 9.6.3.Market analysis, by country

CHAPTER 10:WEARABLE INJECTOR MARKET, BY REGION

  • 10.1.Overview
    • 10.1.1.Market size and forecast
  • 10.2.North America
    • 10.2.1.Key market trends, growth factors, and opportunities
    • 10.2.2.North America wearable injector market, by type
    • 10.2.3.North America wearable injector market, by usage
    • 10.2.4.North America wearable injector market, by technology
    • 10.2.5.North America wearable injector market, by mechanism of action
    • 10.2.6.North America wearable injector market, by therapeutic area
    • 10.2.7.North America wearable injector market, by end user
    • 10.2.8.Market size and forecast, by country
      • 10.2.8.1.U.S.
      • 10.2.8.1.1.U.S. wearable injector market, by type
      • 10.2.8.1.2.U.S. wearable injector market, by usage
      • 10.2.8.1.3.U.S. wearable injector market, by technology
      • 10.2.8.1.4.U.S. wearable injector market, by mechanism of action
      • 10.2.8.1.5.U.S. wearable injector market, by therapeutic area
      • 10.2.8.1.6.U.S. wearable injector market, by end user
      • 10.2.8.2.Canada
      • 10.2.8.2.1.Canada wearable injector market, by type
      • 10.2.8.2.2.Canada. wearable injector market, by usage
      • 10.2.8.2.3.Canada wearable injector market, by technology
      • 10.2.8.2.4.Canada wearable injector market, by mechanism of action
      • 10.2.8.2.5.Canada wearable injector market, by therapeutic area
      • 10.2.8.2.6.Canada wearable injector market, by end user
      • 10.2.8.3.Mexico
      • 10.2.8.3.1.Mexico wearable injector market, by type
      • 10.2.8.3.2.Mexico wearable injector market, by usage
      • 10.2.8.3.3.Mexico wearable injector market, by technology
      • 10.2.8.3.4.Mexico wearable injector market, by mechanism of action
      • 10.2.8.3.5.Mexico wearable injector market, by therapeutic area
      • 10.2.8.3.6.Mexico wearable injector market, by end user
  • 10.3.Europe
    • 10.3.1.Key market trends, growth factors, and opportunities
    • 10.3.2.Europe wearable injector market, by type
    • 10.3.3.Europe wearable injector market, by usage
    • 10.3.4.Europe wearable injector market, by technology
    • 10.3.5.Europe wearable injector market, by mechanism of action
    • 10.3.6.Europe wearable injector market, by therapeutic area
    • 10.3.7.Europe wearable injector market, by end user
    • 10.3.8.Market size and forecast, by country
      • 10.3.8.1.Germany
      • 10.3.8.1.1.Germany wearable injector market, by type
      • 10.3.8.1.2.Germany wearable injector market, by usage
      • 10.3.8.1.3.Germany wearable injector market, by technology
      • 10.3.8.1.4.Germany wearable injector market, by mechanism of action
      • 10.3.8.1.5.Germany wearable injector market, by therapeutic area
      • 10.3.8.1.6.Germany wearable injector market, by end user
      • 10.3.8.2.France
      • 10.3.8.2.1.France wearable injector market, by type
      • 10.3.8.2.2.France wearable injector market, by usage
      • 10.3.8.2.3.France wearable injector market, by technology
      • 10.3.8.2.4.France wearable injector market, by mechanism of action
      • 10.3.8.2.5.France wearable injector market, by therapeutic area
      • 10.3.8.2.6.France wearable injector market, by end user
      • 10.3.8.3.UK
      • 10.3.8.3.1.UK wearable injector market, by type
      • 10.3.8.3.2.UK wearable injector market, by usage
      • 10.3.8.3.3.UK wearable injector market, by technology
      • 10.3.8.3.4.UK wearable injector market, by mechanism of action
      • 10.3.8.3.5.UK wearable injector market, by therapeutic area
      • 10.3.8.3.6.UK wearable injector market, by end user
      • 10.3.8.4.Italy
      • 10.3.8.4.1.Italy wearable injector market, by type
      • 10.3.8.4.2.Italy wearable injector market, by usage
      • 10.3.8.4.3.Italy wearable injector market, by technology
      • 10.3.8.4.4.Italy wearable injector market, by mechanism of action
      • 10.3.8.4.5.Italy wearable injector market, by therapeutic area
      • 10.3.8.4.6.Italy wearable injector market, by end user
      • 10.3.8.5.Spain
      • 10.3.8.5.1.Spain wearable injector market, by type
      • 10.3.8.5.2.Spain wearable injector market, by usage
      • 10.3.8.5.3.Spain wearable injector market, by technology
      • 10.3.8.5.4.Spain wearable injector market, by mechanism of action
      • 10.3.8.5.5.Spain wearable injector market, by therapeutic area
      • 10.3.8.5.6.Spain wearable injector market, by end user
      • 10.3.8.6.Rest of Europe
      • 10.3.8.6.1.Rest of Europe wearable injector market, by type
      • 10.3.8.6.2.Rest of Europe wearable injector market, by usage
      • 10.3.8.6.3.Rest of Europe wearable injector market, by technology
      • 10.3.8.6.4.Rest of Europe wearable injector market, by mechanism of action
      • 10.3.8.6.5.Rest of Europe wearable injector market, by therapeutic area
      • 10.3.8.6.6.Rest of Europe wearable injector market, by end user
  • 10.4.Asia-Pacific
    • 10.4.1.Key market trends, growth factors, and opportunities
    • 10.4.2.Asia-pacific wearable injector market, by type
    • 10.4.3.Asia-pacific wearable injector market, by usage
    • 10.4.4.Asia-pacific wearable injector market, by technology
    • 10.4.5.Asia-pacific wearable injector market, by mechanism of action
    • 10.4.6.Asia-pacific wearable injector market, by therapeutic area
    • 10.4.7.Asia-pacific wearable injector market, by end user
    • 10.4.8.Market size and forecast, by country
      • 10.4.8.1.Japan
      • 10.4.8.1.1.Japan wearable injector market, by type
      • 10.4.8.1.2.Japan wearable injector market, by usage
      • 10.4.8.1.3.Japan wearable injector market, by technology
      • 10.4.8.1.4.Japan wearable injector market, by mechanism of action
      • 10.4.8.1.5.Japan wearable injector market, by therapeutic area
      • 10.4.8.1.6.Japan wearable injector market, by end user
      • 10.4.8.2.China
      • 10.4.8.2.1.China wearable injector market, by type
      • 10.4.8.2.2.China wearable injector market, by usage
      • 10.4.8.2.3.China wearable injector market, by technology
      • 10.4.8.2.4.China wearable injector market, by mechanism of action
      • 10.4.8.2.5.China wearable injector market, by therapeutic area
      • 10.4.8.2.6.China wearable injector market, by end user
      • 10.4.8.3.Australia
      • 10.4.8.3.1.Australia wearable injector market, by type
      • 10.4.8.3.2.Australia wearable injector market, by usage
      • 10.4.8.3.3.Australia wearable injector market, by technology
      • 10.4.8.3.4.Australia wearable injector market, by mechanism of action
      • 10.4.8.3.5.Australia wearable injector market, by therapeutic area
      • 10.4.8.3.6.Australia wearable injector market, by end user
      • 10.4.8.4.India
      • 10.4.8.4.1.India wearable injector market, by type
      • 10.4.8.4.2.India wearable injector market, by usage
      • 10.4.8.4.3.India wearable injector market, by technology
      • 10.4.8.4.4.India wearable injector market, by mechanism of action
      • 10.4.8.4.5.India wearable injector market, by therapeutic area
      • 10.4.8.4.6.India wearable injector market, by end user
      • 10.4.8.5.South Korea
      • 10.4.8.5.1.South Korea wearable injector market, by type
      • 10.4.8.5.2.South Korea wearable injector market, by usage
      • 10.4.8.5.3.South Korea wearable injector market, by technology
      • 10.4.8.5.4.South Korea wearable injector market, by mechanism of action
      • 10.4.8.5.5.South Korea wearable injector market, by therapeutic area
      • 10.4.8.5.6.South Korea wearable injector market, by end user
      • 10.4.8.6.Rest of Asia-Pacific
      • 10.4.8.6.1.Rest of Asia-Pacific wearable injector market, by type
      • 10.4.8.6.2.Rest of Asia-Pacific wearable injector market, by usage
      • 10.4.8.6.3.Rest of Asia-Pacific Rest of Asia-Pacific wearable injector market, by technology
      • 10.4.8.6.4.Rest of Asia-Pacific Rest of Asia-Pacific wearable injector market, by mechanism of action
      • 10.4.8.6.5.Rest of Asia-Pacific Rest of Asia-Pacific wearable injector market, by therapeutic area
      • 10.4.8.6.6.Rest of Asia-Pacific wearable injector market, by end user
  • 10.5.LAMEA
    • 10.5.1.Key market trends, growth factors, and opportunities
    • 10.5.2.LAMEA wearable injector market, by type
    • 10.5.3.LAMEA wearable injector market, by usage
    • 10.5.4.LAMEA wearable injector market, by technology
    • 10.5.5.LAMEA wearable injector market, by mechanism of action
    • 10.5.6.LAMEA wearable injector market, by therapeutic area
    • 10.5.7.LAMEA wearable injector market, by end user
    • 10.5.8.Market size and forecast, by country
      • 10.5.8.1.Brazil
      • 10.5.8.1.1.Brazil wearable injector market, by type
      • 10.5.8.1.2.Brazil wearable injector market, by usage
      • 10.5.8.1.3.Brazil wearable injector market, by technology
      • 10.5.8.1.4.Brazil wearable injector market, by mechanism of action
      • 10.5.8.1.5.Brazil wearable injector market, by therapeutic area
      • 10.5.8.1.6.Brazil wearable injector market, by end user
      • 10.5.8.2.Saudi Arabia
      • 10.5.8.2.1.Saudi Arabia wearable injector market, by type
      • 10.5.8.2.2.Saudi Arabia wearable injector market, by usage
      • 10.5.8.2.3.Saudi Arabia wearable injector market, by technology
      • 10.5.8.2.4.Saudi Arabia wearable injector market, by mechanism of action
      • 10.5.8.2.5.Saudi Arabia wearable injector market, by therapeutic area
      • 10.5.8.2.6.Saudi Arabia wearable injector market, by end user
      • 10.5.8.3.South Africa
      • 10.5.8.3.1.South Africa wearable injector market, by type
      • 10.5.8.3.2.South Africa wearable injector market, by usage
      • 10.5.8.3.3.South Africa wearable injector market, by technology
      • 10.5.8.3.4.South Africa wearable injector market, by mechanism of action
      • 10.5.8.3.5.South Africa wearable injector market, by therapeutic area
      • 10.5.8.3.6.South Africa wearable injector market, by end user
      • 10.5.8.4.Rest of LAMEA
      • 10.5.8.4.1.Rest of LAMEA wearable injector market, by type
      • 10.5.8.4.2.Rest of LAMEA wearable injector market, by usage
      • 10.5.8.4.3.Rest of LAMEA wearable injector market, by technology
      • 10.5.8.4.4.Rest of LAMEA wearable injector market, by mechanism of action
      • 10.5.8.4.5.Rest of LAMEA wearable injector market, by therapeutic area
      • 10.5.8.4.6.Rest of LAMEA wearable injector market, by end user

CHAPTER 11:COMPANY PROFILES

  • 11.1.BECTON DICKINSON AND COMPANY
    • 11.1.1.Company overview
    • 11.1.2.Company snapshot
    • 11.1.3.Operating business segments
    • 11.1.4.Product portfolio
    • 11.1.5.Business performance
  • 11.2.BUHLER MOTOR GmbH
    • 11.2.1.Company overview
    • 11.2.2.Company snapshot
    • 11.2.3.Operating business segments
    • 11.2.4.Product portfolio
    • 11.2.5.Business performance
  • 11.3.ENABLE INJECTION
    • 11.3.1.Company overview
    • 11.3.2.Company snapshot
    • 11.3.3.Operating business segments
    • 11.3.4.Product portfolio
    • 11.3.5.Key strategic moves and developments
  • 11.4.EOFLOW CO. LTD.
    • 11.4.1.Company overview
    • 11.4.2.Company snapshot
    • 11.4.3.Operating business segments
    • 11.4.4.Product portfolio
  • 11.5.GERRESHEIMER ADVANCED TECHNOLOGIES
    • 11.5.1.Company overview
    • 11.5.2.Company snapshot
    • 11.5.3.Operating business segments
    • 11.5.4.Product portfolio
    • 11.5.5.Business performance
    • 11.5.6.Key strategic moves and developments
  • 11.6.INSULET CORPORATION
    • 11.6.1.Company overview
    • 11.6.2.Company snapshot
    • 11.6.3.Operating business segments
    • 11.6.4.Product portfolio
    • 11.6.5.Business performance
    • 11.6.6.Key strategic moves and developments
  • 11.7.MEDTRONIC PLC.
    • 11.7.1.Company overview
    • 11.7.2.Company snapshot
    • 11.7.3.Operating business segment
    • 11.7.4.Product portfolio
    • 11.7.5.Business performance
  • 11.8.UNITED THERAPEUTICS CORPORATION.
    • 11.8.1.Company overview
    • 11.8.2.Company snapshot
    • 11.8.3.Operating business segments
    • 11.8.4.Product portfolio
    • 11.8.5.Business performance
    • 11.8.6.Key strategic moves and developments
  • 11.9.WEST PHARMACEUTICAL SERVICES, INC
    • 11.9.1.Company overview
    • 11.9.2.Company snapshot
    • 11.9.3.Operating business segments
    • 11.9.4.Product portfolio
    • 11.9.5.Business performance
  • 11.10.YPSOMED AG
    • 11.10.1.Company overview
    • 11.10.2.Company snapshot
    • 11.10.3.Operating business segments
    • 11.10.4.Product portfolio
    • 11.10.5.Business performance
    • 11.10.6.Key strategic moves and developments
Back to Top
전화 문의
F A Q